How they work

How Long Does Tirzepatide Stay in Your System?

Tirzepatide has a half-life of about five days, so after a last dose it takes roughly three and a half to four weeks to clear. Here is what the label says about half-life, steady state, missed doses, washout and what happens when you stop.

Last verified September 14, 2026·9 sources cited·Mounjaro Zepbound

Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.

The short answer: tirzepatide has a half-life of about five days, which means most of a dose is gone in roughly three and a half to four weeks after your last injection.

The longer answer involves a few numbers that are worth knowing - how the drug builds up when you start, what happens when you miss a week, and why “out of your bloodstream” and “the effects have worn off” are not the same date on the calendar.

Everything below describes what the FDA-approved labels and published pharmacology say. It is not medical advice, and decisions about starting, changing or stopping any medication belong with a healthcare provider.

What is the half-life of tirzepatide?

Half-life is the time it takes for the amount of a drug in your blood to fall by half.

The Mounjaro label states it directly: “The apparent population mean clearance of tirzepatide is 0.061 L/h with an elimination half-life of approximately 5 days, enabling once-weekly dosing” [1].

The Zepbound label gives a slightly wider figure for its population: “The elimination half-life is approximately 5-6 days in patients with overweight or obesity, and in patients with OSA and obesity” [2].

A population pharmacokinetic model built from 19 pooled studies - covering healthy volunteers, people with kidney and liver impairment, and Phase 1 through Phase 3 participants with type 2 diabetes - landed on a mean half-life of 5.4 days [3].

Phase 1 studies in Japanese and Chinese participants with type 2 diabetes both reported roughly 5 to 6 days as well, so the number holds across populations [4].

How long until tirzepatide is completely out of your body?

Pharmacology uses a rough rule: after five half-lives, about 97 percent of a drug is gone, which is treated as functionally cleared.

At a 5-day half-life, five half-lives is 25 days - about three and a half weeks. At a 6-day half-life, it is 30 days - about four weeks.

An important caveat: that calculation is arithmetic from the labeled half-life. The tirzepatide labels do not publish a “how long until it is gone” figure. Semaglutide’s label does state one (“semaglutide will be present in the circulation for about 5 weeks after the last dose”), which makes the comparison easy: tirzepatide clears faster than semaglutide, because its half-life is shorter [5].

The one place the tirzepatide label does lean on the half-life is the overdose section, which tells clinicians that “a period of observation and treatment for these symptoms may be necessary, taking into account the half-life of tirzepatide of approximately 5 days” [1].

Why does it last so long in the first place?

Natural GIP and GLP-1 survive in the blood for a couple of minutes. Tirzepatide survives for days. Two pieces of engineering explain the difference.

A blocked enzyme cut site. Both natural incretins are chopped apart at their second amino acid by an enzyme called DPP-4. Tirzepatide replaces that residue - and the one at position 13 - with a non-natural amino acid, alpha-aminoisobutyric acid. The enzyme can no longer do its job [1].

A fatty acid anchor. A 20-carbon fatty diacid is attached to lysine 20 through a short linker. That greasy chain binds reversibly to albumin, the most abundant protein in blood. About 99 percent of tirzepatide in circulation is stuck to albumin at any given moment [1]. Only the small free fraction reaches receptors; the bound fraction slowly releases over days. The label describes the chain’s purpose in exactly these terms: it “enables albumin binding and prolongs the half-life.”

How long does it take to build up when you start?

Weekly dosing plus a five-day half-life means the drug accumulates before it plateaus.

Both labels state: “Steady-state plasma tirzepatide concentrations were achieved following 4 weeks of once weekly administration” [1][2]. Population modeling put the accumulation at about 1.7-fold versus a single dose [3]; a four-week Phase 1 study in people with type 2 diabetes measured 1.6-fold based on area under the curve [6].

Two practical consequences follow:

Starting takes about a month to reach a stable level. What you feel in week one is not the plateau.
Every dose increase restarts that clock. This is one of the reasons the labels require at least four weeks between escalation steps, alongside the stated goal of reducing gastrointestinal side effects [1][2].

How fast does a single injection peak?

Slowly, by drug standards. The label reports that after a subcutaneous injection, time to maximum plasma concentration ranges from 8 to 72 hours, with the Zepbound label giving a median of 24 hours [1][2].

Absolute bioavailability is about 80 percent - that is, roughly four fifths of an injected dose reaches the bloodstream [1]. Injection into the abdomen, thigh or upper arm produced similar exposure, so site rotation does not change how much drug you get [1].

What about a missed dose?

Both labels use the same rule, and it differs from semaglutide’s:

If a dose is missed, instruct patients to administer [the drug] as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. [1][2]

The label also allows moving your injection day, “as long as the time between the two doses is at least 3 days (72 hours)” [1].

That four-day window is not arbitrary. Population pharmacokinetic simulations modeled a dose taken four days late and found it produced a transient concentration about 20 percent higher after the following scheduled dose - enough of a bump to define the boundary [3].

For comparison, the Ozempic injection label allows a missed dose to be taken within five days. The two products’ rules are close but not identical, which is a common source of confusion for people who have switched.

What about missing several weeks? Neither label gives a restart schedule. Published clinical conversion guidance suggests re-titration may be appropriate after multiple missed doses, particularly for people who had gastrointestinal trouble the first time, but that is clinician judgment rather than label instruction [7].

How does the body actually get rid of it?

Not by filtering it out whole. Tirzepatide is dismantled.

The label says it “is metabolized by proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid and amide hydrolysis.” The fragments leave in urine and stool, and “intact tirzepatide is not observed in urine or feces” [1].

FDA’s clinical pharmacology review adds the mass balance numbers: in study GPHX, about 70 percent of administered radioactivity was recovered overall, roughly 50 percent in urine and 20 percent in feces [8].

Because tirzepatide is taken apart by general protein-handling machinery rather than by liver enzymes, it does not create the usual drug interaction problems. In vitro studies show low potential for it to inhibit or induce CYP enzymes or block drug transporters [1].

Do kidney or liver problems slow it down?

No, according to the label - and this is unusual for a drug cleared as thoroughly as this one.

Renal impairment does not impact the pharmacokinetics of tirzepatide. [1]

Hepatic impairment does not impact the pharmacokinetics of tirzepatide. [1]

Both statements come from dedicated single-dose 5 mg studies covering mild, moderate and severe impairment, plus end-stage renal disease on the kidney side. No dosage adjustment is recommended for either group [1].

The label does add a monitoring note: kidney function should be watched when starting or escalating in patients with renal impairment who report severe gastrointestinal reactions, because vomiting and diarrhea can cause volume depletion and acute kidney injury [1].

Age, sex, race, ethnicity and body weight also do not have a clinically relevant effect on how the drug behaves [1].

Does the drug leaving your system mean the effects stop?

This is where the calendar gets blurry, and it is worth being precise.

The gastric emptying effect fades on its own, long before the drug does. The label says the stomach-slowing “is largest after the first dose and this effect diminishes over time.” In studies using acetaminophen as a marker, the effect was largely gone by week four at fixed doses [9]. So that particular effect is not a function of blood levels at all.

Appetite and weight follow a different curve. SURMOUNT-MAINTAIN randomized people who had already lost weight on tirzepatide to stay at their maximum tolerated dose, drop to 5 mg, or switch to placebo for a year. At week 112, weight change from baseline was -21.9 percent, -16.6 percent and -9.9 percent respectively. Rescue tirzepatide, offered from week 84 to anyone who had regained at least half the weight they lost, was received by 8 percent of the maximum-dose group and 67 percent of the placebo group [10]. That regain is a physiological process unfolding over months, not the drug washing out over weeks.

Blood sugar responses in type 2 diabetes are managed by a prescriber. Nothing in this article is a plan for stopping a diabetes medication.

What about surgery, anesthesia and procedures?

Both labels carry a Warnings and Precautions item on pulmonary aspiration during general anesthesia or deep sedation, reported in patients receiving GLP-1 receptor agonists undergoing elective procedures. The instruction is to inform healthcare providers of any planned surgeries or procedures [1][2].

Neither label specifies how many days in advance to stop. The literature genuinely disagrees about how much residual stomach-slowing persists with long-term weekly dosing: some analyses report tachyphylaxis - the effect fading - while others argue the acetaminophen absorption test used in most studies underestimates solid-food emptying and that meaningful delay remains [9][11]. That disagreement is exactly why timing decisions belong to the anesthesia and surgical team, who work from professional society guidance rather than a fixed number of days.

Pregnancy planning

Tirzepatide’s US labels warn about potential fetal harm based on animal reproduction studies. Zepbound’s label instructs discontinuation when pregnancy is recognized [2].

Neither US label gives a preconception washout interval. The Canadian product monograph recommends stopping at least one month before planned conception, while US semaglutide labeling specifies at least two months for that different molecule [12]. Reviews written for obstetricians point out that weight loss can restore ovulation in people who previously had difficulty conceiving, which makes proactive planning more important, not less [12].

Anyone planning a pregnancy should raise it with their prescriber rather than working from a number found online.

Quick reference

Question	Answer	Source
Half-life	About 5 days (5-6 days in overweight/obesity); 5.4 days by population model	Labels; popPK [1][2][3]
Time to peak after one dose	8 to 72 hours (median 24 hours)	Labels [1][2]
Bioavailability	About 80%	Label [1]
Time to steady state	4 weeks of weekly dosing	Labels [1][2]
Accumulation	About 1.7-fold	popPK [3]
Estimated washout	About 25 to 30 days (calculated from half-life)	Calculation
Missed dose window	Within 4 days (96 hours)	Labels [1][2]
Minimum gap when changing day	3 days (72 hours)	Labels [1][2]
Kidney/liver adjustment	None recommended	Labels [1][2]
Intact drug in urine or stool	Not observed	Label [1]

Sources

Questions people ask

What is the half-life of tirzepatide?

The Mounjaro label states an elimination half-life of approximately 5 days. The Zepbound label gives approximately 5 to 6 days in people with overweight or obesity and in people with obstructive sleep apnea and obesity. Population modeling across 19 studies put the mean at 5.4 days.

How many days does tirzepatide take to leave your body?

Five half-lives is the usual rule of thumb for near-complete clearance, which works out to roughly 25 days at a 5-day half-life and about 30 days at a 6-day half-life. That is arithmetic from the labeled half-life, not a number the FDA label itself publishes.

How long until tirzepatide reaches full effect in the blood?

Both labels state that steady-state plasma concentrations are reached after 4 weeks of once-weekly dosing. Population modeling found about 1.7-fold accumulation compared with a single dose. Every time the dose is increased, the buildup period effectively starts over for the new level.

What do I do if I miss a dose of Mounjaro or Zepbound?

Both labels say a missed dose can be taken within 4 days (96 hours). If more than 4 days have passed, the label says to skip that dose and take the next one on the regularly scheduled day. The weekly day can be changed as long as at least 3 days (72 hours) separate two doses. Semaglutide's window is 5 days, so the rules differ between drugs.

Does tirzepatide leave the body faster than semaglutide?

Yes. Tirzepatide's half-life is about 5 days; semaglutide's is about a week. The semaglutide label states it 'will be present in the circulation for about 5 weeks after the last dose.' Applying the same logic to tirzepatide gives roughly three and a half to four weeks.

Do kidney or liver problems make tirzepatide stay longer?

According to the label, no. Dedicated studies across mild, moderate and severe kidney impairment including end-stage renal disease, and across mild, moderate and severe liver impairment, found no change in tirzepatide pharmacokinetics. No dosage adjustment is recommended for either.

How long before a planned pregnancy should tirzepatide be stopped?

The US labels do not give a preconception washout interval for tirzepatide. The Canadian product monograph recommends stopping at least one month before planned conception. US semaglutide labeling uses two months for that different molecule. This is a decision to make with a healthcare provider.

Is tirzepatide detectable in urine or stool?

Not as the intact drug. The label states that tirzepatide is broken down by cleaving the peptide backbone, beta-oxidation of the fatty acid, and amide hydrolysis, and that 'intact tirzepatide is not observed in urine or feces.' In the FDA-reviewed mass balance study, about 50 percent of the dose came out in urine and about 20 percent in feces, all as metabolites.

This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.